Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT,Prospective, Multicenter, Single-arm Study
Latest Information Update: 11 Jan 2023
At a glance
- Drugs Lenvatinib (Primary) ; Sintilimab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 05 Jan 2023 Planned initiation date changed from 20 Mar 2022 to 8 Jan 2023.
- 22 Mar 2022 Planned initiation date changed from 5 Feb 2022 to 20 Mar 2022.
- 22 Mar 2022 Status changed from not yet recruiting to recruiting.